Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vyndaqel (Tafamidis) – Treatment for Transthyretin Familial Amyloid Polyneuropathy

FAP is a hereditary disease caused by the mutation of a TTR gene, located on human chromosome 18q12.1-11.2. Image courtesy of Pfizer.



  • Vyndaqel
  • Vyndaqel for FAP
  • Pfizer Vyndaqel
Close
Close
Close

Go Top